(Q84420058)
Statements
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer (English)
Petr Zatloukal
Jaromir Roubec
Karijn Floor
Jaromir Musil
Milan Kuta
Rob J van Klaveren
Subhash Chaudhary
Adrie Gunther
Setareh Shamsili